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Abstract
Background: Cryopreservation of PBMC and/or overnight shipping of samples are required for
many clinical trials, despite their potentially adverse effects upon immune monitoring assays such
as MHC-peptide tetramer staining, cytokine flow cytometry (CFC), and ELISPOT. In this study, we
compared the performance of these assays on leukapheresed PBMC shipped overnight in medium
versus cryopreserved PBMC from matched donors.
Results: Using CMV pp65 peptide pool stimulation or pp65 HLA-A2 tetramer staining, there was
significant correlation between shipped and cryopreserved samples for each assay (p ≤ 0.001). The
differences in response magnitude between cryopreserved and shipped PBMC specimens were not
significant for most antigens and assays. There was significant correlation between CFC and
ELISPOT assay using pp65 peptide pool stimulation, in both shipped and cryopreserved samples (p
≤ 0.001). Strong correlation was observed between CFC (using HLA-A2-restricted pp65 peptide
stimulation) and tetramer staining (p < 0.001). Roughly similar sensitivity and specificity were
observed between the three assays and between shipped and cryopreserved samples for each
assay.
Conclusion: We conclude that all three assays show concordant results on shipped versus
cryopreserved specimens, when using a peptide-based readout. The assays are also concordant
with each other in pair wise comparisons using equivalent antigen systems.
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Background
An increasing number of experimental vaccines are being
developed for diseases in which cellular immunity is
likely to be required for protection [1]. These include HIV
[2], hepatitis C [3], malaria [4], and cancer [5]. In these
settings, immunological monitoring of antigen-specific T
cell responses is likely to be an important part of vaccine
assessment [6-10]. Unfortunately, surrogate markers of
protection have not been established for vaccines that
induce cellular immunity, although correlations between
T cell IFNγ production and clinical responses have been
reported in small numbers of patients [11,12] and in
mouse models [13-17].
Even in the absence of surrogate markers of protection,
the degree to which vaccines can induce T cell responses
can be taken as a measure of immunogenicity, or potency,
and as such can be used to compare different vaccine can-
didates. It is likely that inducing a particular level of anti-
gen-specific T cell response to a vaccine will be necessary,
though perhaps not sufficient, for vaccine efficacy of
either prophylactic or therapeutic vaccines [9,10].
Traditional assays of cellular immunity have been bulk
assays, including proliferation assays measuring 3H-thy-
midine incorporation [18] or cytotoxicity assays measur-
ing 51Cr release [19]. These are increasingly being replaced
by single-cell assays, such as MHC-peptide tetramer stain-
ing [20], cytokine flow cytometry (CFC) – also known as
intracellular cytokine staining (ICS) [21,22], and enzyme-
linked immunospot (ELISPOT) [23]. These assays tend to
be more quantitative, in that they report a fraction of T
cells or PBMC that bind a particular MHC-peptide combi-
nation or that produce a particular cytokine in response to
an antigen.
Comparisons of tetramer, CFC, and/or ELISPOT have
been published [12,24-31], but the relative effect of
PBMC cryopreservation on each of these assays has not
been examined in a side-by-side fashion. It is known that
cryopreservation can negatively impact functional
responses [32-35], particularly to nominal antigens. One
effect of cryopreservation appears to be the loss of antigen
processing capability, as measured by a disproportionate
loss of responses to protein antigens, as compared to pep-
tides [36]. There is also a relationship between viability
post-thawing and capacity for functional responses [37].
The method of cryopreservation can have a tremendous
impact upon viability and function [37-39]. Nevertheless,
some authors have reported equivalent results in ELISPOT
for fresh and frozen samples, when using an optimized
protocol [39-42]. For the present study, an optimized cry-
opreservation protocol was developed (Disis et al., manu-
script submitted) [see Additional file 1]. Two factors that
had a positive impact upon cell viability and recovery, and
which were incorporated into this optimized protocol,
included: (1) the use of human serum albumin as a pro-
tein source in the freezing medium, and (2) the use of
warmed medium for initial dilution of cells after thawing.
Using this optimized cryopreservation protocol, the
present study was conducted in order to determine: (1)
the correlation of fresh and cryopreserved results for
tetramer, CFC, and ELISPOT assays; (2) the sensitivity and
specificity of each assay using CMV seropositive and CMV
seronegative donors; and (3) the inter-assay correlations
using fresh versus optimally cryopreserved cells. Fresh and
cryopreserved PBMC from leukapheresed healthy donors
were overnight shipped, in blinded fashion, to three dif-
ferent laboratories, each of which was an experienced
practitioner of one of the three assays. These laboratories
reported results for their assay to a statistical core, where
the results were compiled and statistical analyses carried
out.
Results
1. Fresh versus cryopreserved assay correlations
PBMC derived from leukapheresis of 20 CMV seropositive
and 21 CMV seronegative donors were analyzed as fresh
samples (overnight shipped) or frozen samples (cryopre-
served then shipped on dry ice). Cells were processed and
analyzed in a blinded fashion by tetramer staining, CFC,
and ELISPOT. Representative data for each assay is shown
in Figure 1. Correlations of fresh versus frozen data were
performed, and are shown in Figure 2.
Fresh versus frozen tetramer results
20 HLA-A0201+ donors (12 CMV seropositive and 8 CMV
seronegative) were analyzed by tetramer staining, using
an HLA-A0201 tetramer loaded with CMV pp65495–503
peptide. Both seropositive and seronegative donors were
analyzed together to determine whether putative negative
results were similar in fresh versus frozen assays, as well as
putative positive results. Frequencies of tetramer+ cells in
fresh versus frozen samples from these donors were signif-
icantly correlated (r = 0.9, 95% C.I.: 0.9–1.0; p < 0.001)
(Figure 2A). To be sure that this was not simply based
upon the correlation of the negative results alone, the sta-
tistics were recalculated on CMV seropositive data only,
and the correlation coefficient remained 0.9 (95% C.I.:
0.7–1.0).
To determine the bias between fresh and frozen samples
from the CMV seropositive donors, the frequency of
tetramer+ cells in frozen samples was subtracted from that
of the respective fresh samples (Figure 2B). The median
difference in responses was -0.008 (95% C.I.: -0.2 to
0.07). The Wilcoxon signed-rank test was unable to detect
a significant bias towards either sample type.BMC Immunology 2005, 6:17 http://www.biomedcentral.com/1471-2172/6/17
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Representative data from the three assays on the same CMV seropositive donor PBMC Figure 1
Representative data from the three assays on the same CMV seropositive donor PBMC. (A) Tetramer staining 
after gating as described in the Methods. Background seen in staining of fresh cells with negative tetramer was caused by 
streptavidin-PE. Frozen cells were stained with a different lot of negative tetramer. (B) CFC staining after gating as described in 
the Methods. (C) ELISPOT data as analyzed on the Automated Reader System as described in the Methods. Error bars repre-
sent the S.D. of 6 replicates.
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Correlation of fresh-shipped and cryopreserved samples in all three assays Figure 2
Correlation of fresh-shipped and cryopreserved samples in all three assays. (A, C, E) Correlation graphs of fresh-
shipped versus cryopreserved PBMC samples for tetramer, CFC, and ELISPOT, respectively. Correlation coefficients (r) are 
shown for all data as well as for CMV seropositive donors only. Open symbols represent CMV seronegative donors; closed 
symbols, seropositive donors (*, CMV serostatus unknown). The diagonal line represents the line of perfect agreement 
between the assays. (B, D, F) Within-donor differences are shown for fresh-shipped versus cryopreserved responses. Bars rep-
resent the median difference of all donors. All statistics are based on a natural logarithm transformation, which was done to 
better approximate a bivariate normal distribution.
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Fresh versus frozen CFC
CD8+ T cell IFNγ production was measured by CFC using
two different CMV antigens for stimulation: (1) a mixture
of overlapping peptides corresponding to the CMV pp65
protein; and (2) the pp65495–503 peptide. The former stim-
ulus was used for comparison to ELISPOT, while the latter
allowed comparison to tetramer staining. CFC responses
in fresh and frozen PBMC samples from all donors corre-
lated significantly with both antigens. The estimated cor-
relation coefficient for CMV pp65 peptide mix stimulated
samples was 0.6 (95% C.I.: 0.4–0.8) (p < 0.001), and that
for CMV-A2 peptide stimulated samples was 0.8, (95%
C.I.: 0.6–0.8) (p < 0.001) (Figure 2C). These coefficients
did not change noticeably when only CMV seropositive
data points were considered (r = 0.7 (95% C.I.: 0.3–0.9)
and 0.8 (95% C.I.: 0.4–0.9), respectively). Positive corre-
lation of fresh and frozen samples was also observed for
SEB-stimulated samples (r = 0.5, p = 0.002; data not
shown).
To determine a bias towards a particular sample type, the
difference between responses of fresh and frozen samples
from CMV seropositive donors were calculated (Figure
2D). The median difference in responses to CMV-A2 pep-
tide was -0.04 (95% C.I.: -0.22 to 0.00) and the median
difference to CMV pp65 peptide mix was 0.13 (95% C.I.:
0.04–0.34). The Wilcoxon signed-rank test was unable to
detect a significant bias towards either sample type stimu-
lated with either of the two CMV antigens. However, there
was a trend toward higher fresh responses to CMV pp65
peptide mix (p = 0.06).
CFC responses to pp65 peptide mix and SEB in CD4+ T
cells were also measured, and showed similar correlation
between fresh and frozen samples (r = 0.6 and 0.4, respec-
tively, with p < 0.001 for both stimuli) (data not shown).
Fresh versus frozen ELISPOT
IFNγ producing cells were measured by ELISPOT using
either CMV pp65 peptide mix or SEB, and enumerated in
replicates of 6 wells. The responses of fresh and frozen
samples from all donors correlated significantly for pp65
peptide mix stimulation (r = 0.9, 95% C.I.: 0.8–0.9; p <
0.001) (Figure 2E). The correlation coefficient was some-
what lower when only CMV seropositive data points were
considered (r = 0.7, 95% C.I.: 0.4–0.9). Interestingly, no
significant correlation was observed for SEB activated
samples (data not shown).
Fresh versus frozen bias was determined by subtracting
pp65 peptide mix responses of frozen samples from their
respective fresh samples, for CMV seropositive donors
(Figure 2F). The median difference in responses was -12.5,
(95% C.I.: -2 to -34). There was a significant bias toward
higher responses in frozen samples (p = 0.04).
2. Sensitivity and specificity measurements
To further characterize the relative performance of the
three assays, they were examined for their ability to pre-
dict CMV serostatus, using fresh and frozen PBMC. Side-
by-side dot plots (Figure 3) show the results on CMV
seronegative versus seropositive donors for each assay.
Sensitivity was defined as the proportion of CMV seropos-
itive donors correctly identified using a particular cutoff,
while specificity was defined as 1 – the false positive rate
at that cutoff. These values vary inversely with each other,
depending upon the cutoff value used to classify results as
positive or negative. To quantitatively compare assay per-
formance, the highest attainable specificity for a sensitiv-
ity of ≥90% (if achievable) was reported for each assay
(Table 1).
Sensitivity and specificity of tetramer staining
For tetramer staining on fresh samples (Figure 3A), the
median number of tetramer+ cells was 0.02% for CMV
seronegative donors, and 0.26% for CMV seropositive
donors (n = 8 and 12, respectively). For frozen samples
(Figure 3B), these medians were 0.01% and 0.26%,
respectively.
A positive/negative cutoff of 0.03% for fresh samples and
0.02% for cryopreserved samples was determined as
described above. Neither sample type yielded 100% sensi-
tivity and specificity (Table 1). Additionally, there was no
consistent change in sensitivity and specificity between
fresh and cryopreserved data sets.
Sensitivity and specificity of CFC
For fresh CFC samples (Figure 3C), the median response
was 0.07% for seronegative donors and 0.71% for serop-
ositive donors (n = 20 and 21, respectively). For frozen
samples (Figure 3D), these medians were 0.01% and
0.58%, respectively.
For CMV pp65 peptide mix stimulation, positive/negative
cutoff values of 0.13% for fresh samples and 0.05% for
frozen samples were calculated as described above. For
CMV pp65495–503 peptide stimulation, the cutoffs were
0.08% for both fresh and frozen samples. Again, none of
these assays reached 100% sensitivity and specificity
(Table 1). There was also no consistent change in sensitiv-
ity and specificity between fresh and cryopreserved data
sets.
Sensitivity and specificity of ELISPOT
For fresh ELISPOT samples (Figure 3E), the median
number of SFC was 0 for seronegative donors and 34 for
seropositive donors. For frozen samples (Figure 3F), these
medians were 1 and 67, respectively. These numbersBMC Immunology 2005, 6:17 http://www.biomedcentral.com/1471-2172/6/17
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Results of the three assays on CMV seronegative versus seropositive donors Figure 3
Results of the three assays on CMV seronegative versus seropositive donors. (A and B) Tetramer results on fresh-
shipped and cryopreserved PBMC samples, respectively. (C and D) CFC results on fresh-shipped and cryopreserved PBMC 
samples, respectively. (E and F) ELISPOT results on fresh-shipped and cryopreserved PBMC samples, respectively. The dotted 
line represents the suggested cutoff based upon maximum specificity for sensitivity ≥90%, or that which obtains maximum sen-
sitivity if maximum sensitivity <90%.
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reiterate the bias in ELISPOT toward higher responses in
frozen versus fresh samples in this study.
When positive/negative cutoff values were calculated as
above, these were 4 SFC for fresh samples and 16 SFC for
frozen samples. As with the other assays, 100% sensitivity
and specificity was not reached (Table 1). Also, there was
no consistent change in sensitivity and specificity between
fresh and cryopreserved data sets.
Another way to compare sensitivity and specificity
between assays and formats is to plot the sensitivity versus
false positive rate in an ROC plot, and then calculate the
area under this curve. The greater the area, the greater the
ability of the assay to discriminate positive from negative
samples. In comparing these areas (Table 1), no statisti-
cally significant differences were found between fresh and
frozen samples for any of the assays, or between CFC and
ELISPOT, or CFC and tetramer (all p values >0.05). This is
despite the fact that tetramer and CFC results were calcu-
lated only for defined subsets of cells, whereas all PBMC
were used in ELISPOT. Better discrimination might be
obtained for CFC if CD4+  T cell responses were also
included, or for tetramer if class II and/or additional class
I epitope tetramers had been used. In fact, when CFC
responses for pp65 peptide mix were recalculated to
include all IFNγ+ PBMC, not just CD8+ T cells, the area
under the ROC curve was, on average, higher (0.890 for
fresh, 0.915 for frozen PBMC), but still not significantly
different from ELISPOT.
3. Inter-assay correlations
Two-way correlations were performed between tetramer
staining and CFC, and between CFC and ELISPOT (Figure
4). CMV pp65495–503-specific responses obtained using
CFC were compared to HLA-A0201 pp65495–503 tetramer
staining for all 20 HLA-A0201+ donors in the study (12
CMV seropositive, 8 CMV seronegative). CMV pp65 pep-
tide mix-specific responses obtained by CFC and ELISPOT
were compared for all 20 CMV seropositive and 21 CMV
seronegative donors in the study.
Tetramer staining versus CFC
These assays correlated significantly with each other for
both fresh and frozen samples (Figures 4A and 4B). The
estimated correlation coefficient was 0.9 for both fresh
and frozen samples (95% C.I.: 0.8–1.0 for both) (p <
0.001 for both). These were the strongest inter-assay cor-
relations observed in this study.
CFC versus ELISPOT
A significant correlation between these two assays was
observed using both fresh and frozen PBMC samples
(data not shown). The estimated correlation coefficient
was 0.5 (95% C.I.: 0.2–0.7) (p = 0.001) for fresh samples,
and 0.7 (95% C.I.: 0.5–0.8) (p < 0.001) for frozen sam-
ples. However, when only CMV seropositive donors were
considered, the p values became non-significant for both
fresh and frozen samples. Thus, CFC and ELISPOT were
less tightly correlated than tetramer and CFC. This is in
agreement with another published report comparing
ELISPOT and CFC [29].
The scales and readouts of CFC and ELISPOT are very dif-
ferent (%IFNγ+ CD8+ T cells versus SFC per 105 PBMC). To
correct for these differences, the CFC results were
expressed as the total number of IFNγ+ cells per 105 PBMC,
without gating on CD3 or CD8. This mimicked the
readout of the ELISPOT assay, which reported positive
events per 105 PBMC (the number of cells plated in each
ELISPOT well). The estimated correlation coefficients
under these conditions were 0.7 for both fresh (95% CI:
0.4–0.8) and frozen (95% CI: 0.5–0.8) samples (p <
0.001 both) (Figure 4C and 4D). When only CMV
seropositive samples were considered, the correlation
coefficients became 0.8 (95% CI: 0.5–0.9) and 0.4 (95%
Table 1: Cutoffs, sensitivity, and specificity from ROC curves
Assay Antigen Sample Type Cutoff Point1 Sensitivity Specificity Area Under ROC Curve2
Tetramer (% +) CMV pp65 A2 peptide Fresh 0.05 92% 88% 0.906+/-0.076
Cryo. 0.02 83% 100% 0.875+/-0.086
CMV pp65 peptide mix Fresh 0.13 90% 71% 0.819+/-0.075
CFC (% +) Cryo. 0.05 90% 76% 0.920+/-0.046
CMV pp65 A2 peptide Fresh 0.08 75% 100% 0.844+/-0.084
Cryo. 0.08 83% 88% 0.891+/-0.074
ELISPOT (# SFC) CMV pp65 peptide mix Fresh 4 95% 94% 0.982+/-0.018
Cryo. 16 90% 100% 0.985+/-0.015
1Cut-off is that which achieves maximum specificity for sensitivity ≥90%, or that which obtains maximum sensitivity if maximum sensitivity <90%.)
2Values are given +/- standard error.BMC Immunology 2005, 6:17 http://www.biomedcentral.com/1471-2172/6/17
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Inter-assay correlations Figure 4
Inter-assay correlations. (A and B) Correlation of tetramer staining and CFC in fresh-shipped and cryopreserved PBMC 
samples, respectively. (C and D) Correlation of ELISPOT and CFC in fresh-shipped and cryopreserved PBMC samples, respec-
tively, with CFC results reported as number of IFNγ+ cells per 105 PBMC. In panels C-D, the mean of 6 replicates is shown for 
all ELISPOT data. Correlation coefficients (r) are shown for all data as well as for CMV seropositive donors only. Open sym-
bols represent CMV seronegative donors; closed symbols, seropositive donors (*, CMV serostatus unknown). The diagonal 
line represents the line of perfect agreement between the assays.
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CI: 0.0–0.7), respectively (p < 0.001 and p = 0.06, respec-
tively). Thus, expression of the CFC results in this format
appeared to improve the correlation. This may reflect the
response of non-CD8+ cells in these assays. Note also that
when CFC results were plotted in this way, there were on
average several-fold higher responses with CFC versus
ELISPOT (as represented by most points being above the
diagonal in Figures 4C and 4D).
Discussion
This study represents a comprehensive analysis of the
effect of cryopreservation (using an optimized cryopreser-
vation protocol) on tetramer, CFC, and ELISPOT assays
using peptide-based antigens. Each assay was individually
optimized by a laboratory experienced in that technique,
to ensure the best possible performance for each. For
example, costimulatory antibodies (CD28 and CD49d)
were used in CFC but not ELISPOT, despite the fact that
addition of CD28 antibody can improve ELISPOT sensi-
tivity [43]. In our hands, occasional donors developed
unacceptably high ELISPOT backgrounds (>100 spots per
106 PBMC) with the use of CD28 costimulation (data not
shown), so it was not used for that assay, although it was
used for CFC. While there are shortcomings of this study
design, we felt that this provided the fairest and most
robust way to compare these assays. The assays were com-
pared by correlation of results for fresh and frozen sam-
ples; by analyzing sensitivity and specificity of each assay
on fresh and frozen samples; and by determining inter-
assay correlations using fresh and frozen samples. The
overall findings are summarized in Table 2.
None of the three assays showed a significant reduction of
signal in frozen cells relative to fresh cells. The fresh-to-
frozen correlation was strongest for tetramer staining,
which does not rely on cell function, then CFC and ELIS-
POT. Compared to CMV responses, SEB responses were
less well correlated in fresh and frozen samples using CFC,
and not at all correlated using ELISPOT. The reasons for
this are not clear; however, they may stem from the rela-
tive affinities of T cells responding to CMV peptides versus
SEB. It is known that T cells bearing a number of different
TCR Vβ sequences can participate, to varying degrees, in
the SEB response. The participation of different Vβ fami-
lies is related to their affinity for SEB. Low affinity Vβ
responses may be preferentially lost upon cryopreserva-
tion. The differential representation of these Vβ subsets in
different donors may thus lead to inconsistencies in the
correlation of fresh to cryopreserved responses for SEB.
CMV responses may be of generally uniform and higher
affinity, as suggested by their typically bright, clustered
IFNγ staining (compared to SEB responses, where IFNγ
staining tends to be more of a smear). If this is true, it may
also suggest that other low-affinity responses, such as
those to tumor antigens, may be more susceptible to loss
upon cryopreservation; this needs to be tested.
Rather than compare cryopreserved PBMC to fresh, same-
day activated PBMC, the former were compared to fresh,
overnight-shipped PBMC from leukapheresed donors.
Since some functional degradation undoubtedly occurs
with overnight shipping, this is not ideal in terms of
assessing the total signal loss due to cryopreservation.
However, the reality of large clinical studies is that PBMC
will in all likelihood be cryopreserved and/or shipped
overnight to a laboratory that does immunological moni-
toring. Thus, comparison of these two conditions repre-
sents a comparison of two likely scenarios for handling of
PBMC samples in clinical trials. The current results imply
that there is unlikely to be a pronounced difference in
results with any of the three assays when using either of
these conditions. It is unknown whether a detectable loss
of signal would be observed if PBMC were subjected to
both overnight shipping and then cryopreservation. Of
course, all of these data assume that reasonable care is
taken in sample cryopreservation and shipping, which
were optimized for this study (Disis et al., manuscript sub-
mitted). Also, the stability of healthy donor cells, as used
in this study, may be superior to those from certain dis-
ease states, e.g., HIV or tumor patients. Finally, the use of
shipped PBMC (rather than whole blood) may have
improved the results seen in this study; thus our results
should not be taken as indicative of what would be
achieved if whole blood samples were shipped overnight.
Table 2: Summary of assay characteristics
Assay Type of assay Readout Fresh to frozen correlation Sensitivity and specificity1 Inter-assay correlations
Tetramer Phenotypic 4-color flow cytometry r = 0.9 >70%2 r = 0.9
CFC Functional 4-color flow cytometry r = 0.6 (CMV)
r = 0.4 (SEB)
>70%2 r = 0.9
r = 0.7
ELISPOT Functional Plate reader r = 0.6 (CMV)
NS (SEB)
>90% r = 0.7
1For both fresh and frozen samples with all peptide-based stimuli.
2Potentially higher if multiple tetramers or CD4 and CD8 responses are considered.BMC Immunology 2005, 6:17 http://www.biomedcentral.com/1471-2172/6/17
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Because this study used peptide-based antigens (and SEB),
drastic loss of functional responses as reported for whole-
protein antigens [36] were not seen. The current results
should not be interpreted to apply to non-peptide anti-
gens, since antigen-processing capabilities are preferen-
tially lost upon cryopreservation.
We defined sensitivity and specificity on the basis of reac-
tivity with donors who were CMV seropositive, and lack of
reactivity with donors who were CMV seronegative. This
comparison is not ideal, since there are reports of non-cor-
relation of serological and T cell responses to CMV [44].
In particular, assays examining a single epitope response
(e.g., tetramer and CFC for pp65495–503) may underesti-
mate CMV responders, due to immunodominance hierar-
chies [45]. HLA-A2-restricted responses to pp65495–503 are
known to be suppressed in individuals co-expressing
HLA-B7 [46], and such individuals were not excluded
from this study. However, CFC assays using pp65 peptide
mix were found in at least one previous study to differen-
tiate CMV seropositive and seronegative donors with
100% sensitivity and specificity, although the sample size
was small (15 seropositive and 14 seronegative donors)
[47]. All three assays were recently compared in a study of
fresh PBMC from 21 CMV seropositive and 20 CMV
seronegative healthy donors, with a sensitivity of 87.5%
and specificity of 100% for each assay [48].
None of the three assays attained 100% sensitivity and
specificity using either fresh or cryopreserved PBMC in the
present study. ELISPOT, especially on cryopreserved
PBMC, showed slightly greater sensitivity (for specificity
≥90%) than did CFC or tetramer (although the difference
was not statistically significant). This was partly due to the
reactivity of one or two seronegative donors in the CFC
and tetramer assays. This reactivity was more pronounced
in the assays with fresh PBMC, but was still present in the
cryopreserved PBMC from the same donors. In the case of
CFC, the cryopreserved PBMC assay was repeated on addi-
tional cells and still showed a similar level of reactivity,
suggesting that it was not due to a technical error. It is pos-
sible that these donors represented true discordant
responses between serological and cellular assays.
The quantitative comparison of tetramer and CFC resulted
in the tightest correlation. This could be related to the fact
that both of these assays use the same readout platform
(flow cytometry). The correlation of CFC and ELISPOT
was less precise, and was not statistically significant when
CMV seronegative donors were excluded. The correlation
appeared tighter when CFC results were expressed as a
proportion of all PBMC. This could be due to variable pro-
portions of CD4+ T cells contributing to the response to
pp65 peptide mix. It is also possible that non-T cells con-
tribute to this response, although this was not directly
assessed in this study.
Conclusion
We conclude that tetramer, CFC, and ELISPOT assays can
be performed on optimally cryopreserved PBMC with
minimal or no loss of signal when compared to fresh,
overnight-shipped PBMC. The assays correlate signifi-
cantly in direct comparisons using the same antigen sys-
tems, whether fresh or cryopreserved PBMC are used. The
strongest correlations of fresh and cryopreserved PBMC
are seen with tetramer and CFC assays; and these two
assays also correlate most strongly with each other. All
three assays showed roughly similar sensitivity and specif-
icity in discriminating CMV seropositive from seronega-
tive donors. The strong correlation of tetramer and CFC
assays in fresh and cryopreserved cells, along with their
multiparameter information content, make them ideal
choices for immune monitoring assays.
Methods
PBMC isolation and processing
PBMC from leukapheresis (obtained from healthy donors
without cytokine mobilization) were isolated using Ficoll
gradient separation. Briefly, 5 ml of leukapheresis product
were aliquoted into 50 ml conical tubes (BD Falcon, Fran-
klin Lakes, NJ) washed once by adding HBSS (Gibco Inv-
itrogen Corporation, Grand Island, NY) and centrifuged
for 10 minutes at 280 × G. The pelleted cells were resus-
pended and 40 ml of HBSS were added. Ten ml of Ficoll
Paque (Amersham Biosciences, Piscataway, NJ) were care-
fully underlayed and the tubes centrifuged at 400 × G for
40 minutes. The buffy coat was collected and washed
twice with HBSS. Viability was assessed using 0.4%
Trypan blue (Sigma, St. Louis, MO). For fresh-shipped
specimens, 2 × 107 viable lymphocytes were resuspended
in 50 ml RPMI+10% fetal bovine serum and shipped over-
night at ambient temperature in a 50 ml conical tube
packed in an insulated foam container. Fresh-shipped
PBMC were centrifuged as soon as received and the assays
set up as described below.
Cryopreservation [see Additional file 1]
To cryopreserve PBMC, 2X freezing media was first pre-
pared, containing 20% DMSO in RPMI (Sigma Chemical
Co., St. Louis, MO) containing 12.5% human serum albu-
min (HSA) (Gemini Bioproducts, Woodland, CA), and
cooled on ice for a minimum of 30 minutes. Ficolled
PBMC at 2 × 107 viable lymphocytes/ml were resuspended
in cooled RPMI+12.5% HSA with no DMSO. An equal
volume of chilled 2X freezing media was added to the cell
suspension dropwise, while gently swirling the tube. One
ml of this cell suspension was aliquoted into each cryovial
(Sarstedt, Inc., Newton, NC). Once aliquoted, cryovials
were placed on ice and then transferred into a freezingBMC Immunology 2005, 6:17 http://www.biomedcentral.com/1471-2172/6/17
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container (Nalgene, Rochester, NY), and stored at -80°C
for 24 hours. Cryovials were then transferred into liquid
nitrogen for long-term storage. After 30 days, cryovials
were overnight shipped on dry ice to the recipient
laboratories.
Thawing [see Additional file 1]
Cryopreserved PBMC were stored at -80°C until thawing
to set up the assays. Cryopreserved cells were thawed and
slowly diluted with 8 ml of warm RPMI+10% fetal bovine
serum+antibiotics (cRPMI-10, all components from
Sigma). The cells were centrifuged for 7 minutes at 250 ×
G, then resuspended as described below for each assay.
Viability and recovery were checked using Trypan blue,
and were >80% and >50%, respectively, in all samples.
MHC class I-peptide tetramer staining
Fresh and frozen PBMC from 12 CMV seropositive and 8
CMV seronegative patients were screened with MHC
tetramer composed of HLA-A*0201 monomers carrying
the CMV pp65495–503 peptide epitope (NLVPMVATV). For
flow cytometry analysis, the Multiple Antibody Single
Color protocol (iMASC, Beckman Coulter Inc., Fullerton,
CA) was used. Briefly, ten µl each of CD4, CD13, and
CD19 antibodies conjugated to PE-Cy5 (PC5) were added
to sample tubes in order to exclude CD4 T cells, granulo-
cytes, and B cells from analysis. In addition, 10 µl of CD8
FITC and 10 µl tetramer PE were added, followed by 1 ×
106 PBMC in 100 µl of flow cytometry buffer (HBSS con-
taining 0.1% bovine serum albumin, 0.02% sodium
azide). Samples were incubated for 30 minutes at room
temperature followed by a wash with flow cytometry
buffer and fixation in 1% formaldehyde. Samples were
run on a BD FACSCalibur flow cytometer that was set to
acquire 30,000 CD8+ T cells. Analysis was performed
using CellQuest software (BD Biosciences, San Jose, CA)
and gating was done to accept CD8+ /tetramer+ cells and to
exclude PC5-positive cells.
Cytokine flow cytometry
CFC assays were performed according to a previously pub-
lished method [49,50]. 200 µl containing 2 × 106 PBMC
in cRPMI-10 medium were plated per well in 96-well
round-bottom plates. For cryopreserved PBMC, the
thawed cells were then rested at 37°C, 7% CO2 overnight.
For both fresh and cryopreserved PBMC, activation rea-
gents (stimulus + brefeldin A) were added in a volume of
20 µl per 200 µl of cell suspension per well and the cells
were then incubated at 37°C for 6 hours. Stimuli included
CMV pp65 peptide mix (BD Biosciences; used at a final
concentration of 1.7 µg/ml/peptide); CMV pp65495–503
peptide (SynPep Corp., Dublin, CA; used at a final con-
centration of 10 µg/ml); and SEB (Sigma; used at a final
concentration of 1 µg/ml). All samples received a final
concentration of 1 µg/ml each of CD28+CD49d costimu-
latory antibodies and 10 µg/ml of brefeldin A (both from
BD Biosciences). After 6 hours incubation, the cells were
treated with 2 mM final concentration of EDTA for 15
minutes at room temperature, then fixed with FACS Lys-
ing Solution (BD Biosciences) and stored at -80°C. When
ready to stain, the frozen plates were thawed at 37°C and
processed further with FACS Permeabilizing Solution 2
(BD Biosciences) followed by staining with IFNγ FITC/
CD69 PE/CD8 PerCPCy5.5/CD3 APC (BD Biosciences)
for 1 hour at room temperature. Plates were washed and
cells resuspended in 1% paraformaldehyde in PBS.
Samples were acquired within 24 hours of staining using
a FACSCalibur flow cytometer with a Multiwell Autosam-
pler, using Multiwell Plate Manager and CellQuest Pro
software (BD Biosciences). 40,000 CD3+CD8+  lym-
phocytes were collected per sample. A "response region"
was set around double-positive cells in a gated dot plot
displaying CD69 versus IFNγ staining from an SEB-stimu-
lated sample. This response region was then applied to all
samples to determine the percentage of cytokine-positive
cells. Data were reported as the net percent of CD3+CD8+
lymphocytes that were IFNγ+  after subtracting the
response of unstimulated samples.
ELISPOT
PBMC were assayed for IFNγ production in the presence
of CMV pp65 peptide mix (BD Biosciences), SEB, and
media in replicates of 6. Multiscreen-HA 96-well plates
(Millipore, Bedford, MA) were coated overnight at 4°C
with 100 µl/well of 10 µg/ml mouse anti-human IFNγ
mAb 7-D1K (diaPharma Group, Inc., West Chester, OH)
in Dulbecco's Phosphate Buffered Saline (DPBS) (Gibco
Invitrogen). The plates were washed 3 times for 5 minutes
each with 150 µl DPBS/well and blocked with 150 µl/well
of RPMI-1640, 10% human AB serum, 25 mM HEPES,
100 U/ml penicillin, 100 µg/ml streptomycin, and 2 mM
L-glutamine for 1 hour at 37°C in 5% CO2. PBMC were
plated at 100,000 per well with 1:800 of CMV pp65
peptide mix (approximately 1.75 µg/ml of each peptide),
100 ng/ml of SEB, or media in a total volume of 200 µl/
well for 18–24 hours at 37°C in 5% CO2.
The plates were washed with 0.05% Tween/DPBS using a
Tecan 96PW plate washer (Tecan, Research Triangle Park,
NC). A solution of 100 µl of mouse anti-human IFNγ
biotinylated mAb 7-B6-1 (diaPharma) at 1 µg/ml in DPBS
was added to each well and the plates incubated for 2
hours at 37°C, 5% CO2. Vectastain ABC Peroxidase (Vec-
tor Labs, Inc., Burlingame, CA) was added at 100 µl/well
for 1 hour at room temperature after washing with 0.05%
Tween/DPBS using the Tecan plate washer. The plates
were washed for the last time with 0.05% Tween/DPBS
followed by DPBS. Color was developed using 100 µl/well
of 3-amino-9-ethyl-carbazole [AEC] (Sigma) reconsti-BMC Immunology 2005, 6:17 http://www.biomedcentral.com/1471-2172/6/17
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tuted in an acetate buffer for 4 minutes at room tempera-
ture in the dark. Color development was stopped with
deionized water. Basins were removed and the mem-
branes dried overnight in the dark. Membranes were
attached to sealing tape (Millipore, Bedford, MA) and the
number of spots per well was determined using a KS ELIS-
POT Automated Reader System with KS ELISPOT 4.2 Soft-
ware (Carl Zeiss, Inc., Thornwood, NY). The mean
number of spots from the six replicate wells at each dilu-
tion was reported for each antigen. The analyses in this
paper were based on the wells containing 1 × 105
responder PBMC, which is the dilution that yielded the
highest ratio of spots/PBMC (data not shown).
Statistical analyses
All samples tested were included in the analysis, as no
attempt was made to exclude outliers. Tests of correlations
between fresh and frozen samples were performed using
the Pearson Product Moment Correlation Coefficient on
the natural logarithm of responses. This transformation
was performed to correct for observed skewness in the
data, since the statistical test assumes a bivariate normal
distribution. However, the significance of the correlations
was largely unchanged when untransformed data was
used. If the net response equaled zero, a small constant
was added (0.004 for % positive and 1 for cells/105
PBMC) prior to computing the natural log. The Wilcoxon
Signed-Rank test was performed for differences between
paired fresh and frozen samples. Tests of correlations
between assays were performed using the Pearson Product
Moment Correlation Coefficient after natural logarithmic
transformation and adjustment for zeroes.
For each assay and antigen combination, the operating
characteristics were summarized in terms of the sensitivity
and false positive rate (1-specificity) for cut-off values of
net response of both fresh and frozen samples. The sensi-
tivity and false positive rate were defined as the propor-
tion of correctly identified CMV seropositive samples and
incorrectly identified seronegative samples, respectively,
with an assay response exceeding each cut-off value. The
ROC curve was constructed as a plot of the false positive
test rate versus sensitivity for all cut-off values in the range
of assay responses observed. For each ROC curve, the sen-
sitivity and specificity was reported for the cut-off that
maximized specificity subject to the constraint that sensi-
tivity  ≥90%; or alternatively, if the sensitivity was
bounded below 90%, at the specificity corresponding to
the maximum sensitivity. Tests for differences in the areas
under the ROC curves were performed using the nonpar-
ametric test for correlated data of Delong et al [51]. The
ROC analysis was performed with Stata version 7 software
(StataCorp LP, College Station, TX). All other statistical
analyses were performed with SAS version 9 software (SAS
Institute, Cary, NC).
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